161 related articles for article (PubMed ID: 11594251)
1. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience.
Miravitlles M; Ros F; Cobos A; Kubin R; Tillotson G
Int J Clin Pract; 2001 Sep; 55(7):437-41. PubMed ID: 11594251
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study.
Miravitlles M; Anzueto A; Ewig S; Legnani D; Stauch K
Ther Adv Respir Dis; 2009 Dec; 3(6):267-77. PubMed ID: 19880426
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
Urueta-Robledo J; Ariza H; Jardim JR; Caballero A; García-Calderón A; Amábile-Cuevas CF; Hernández-Oliva G; Vivar-Orozco R;
Respir Med; 2006 Sep; 100(9):1504-11. PubMed ID: 16504492
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
[TBL] [Abstract][Full Text] [Related]
6. Improving care for patients with respiratory tract infections.
Lode H; Garau J
J Chemother; 2002 Feb; 14 Suppl 2():22-8. PubMed ID: 12003137
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective.
Lorenz J; Thate-Waschke IM; Mast O; Kubin R; Rychlik R; Pfeil T; Daniel D; Tillotson GS
J Int Med Res; 2001; 29(2):74-86. PubMed ID: 11393351
[TBL] [Abstract][Full Text] [Related]
9. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
Talan DA
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
[TBL] [Abstract][Full Text] [Related]
10. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Starakis I; Gogos CA; Bassaris H
Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
[TBL] [Abstract][Full Text] [Related]
11. [Clinical contribution of the newer fluoroquinolones in acute bacterial exacerbation of chronic bronchitis].
Niederman MS
Medicina (B Aires); 1999; 59 Suppl 1():23-30. PubMed ID: 10436551
[TBL] [Abstract][Full Text] [Related]
12. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
Chodosh S; DeAbate CA; Haverstock D; Aneiro L; Church D
Respir Med; 2000 Jan; 94(1):18-27. PubMed ID: 10714475
[TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
Ball P
Int J Clin Pract; 2000 Jun; 54(5):329-32. PubMed ID: 10954961
[TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients.
Lorenz J; Busch W; Thate-Waschke IM;
J Int Med Res; 2001; 29(2):61-73. PubMed ID: 11393350
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
Klossek JM; Siegert R; Nikolaidis P; Arvis P; Leberre MA;
J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with moxifloxacin in patients with respiratory tract infections.
Faich GA; Morganroth J; Whitehouse AB; Brar JS; Arcuri P; Kowalsky SF; Haverstock DC; Celesk RA; Church DA
Ann Pharmacother; 2004 May; 38(5):749-54. PubMed ID: 15026565
[TBL] [Abstract][Full Text] [Related]
17. Acute bacterial maxillary sinusitis: time to symptom resolution and return to normal activities with moxifloxacin.
Johnson P; Adelglass J; Rankin B; Sterling R; Keating K; Benson A; Pertel P
Int J Clin Pract; 2008 Sep; 62(9):1366-72. PubMed ID: 18671753
[TBL] [Abstract][Full Text] [Related]
18. The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis.
Wilson R; Macklin-Doherty A
Expert Rev Respir Med; 2012 Nov; 6(5):481-92. PubMed ID: 23113693
[TBL] [Abstract][Full Text] [Related]
19. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.
Schaberg T; Möller M; File T; Stauch K; Landen H
Clin Drug Investig; 2006; 26(12):733-44. PubMed ID: 17274680
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.
Landen H; Möller M; Tillotson GS; Kubin R; Höffken G
J Int Med Res; 2001; 29(2):51-60. PubMed ID: 11393349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
